Novel thiazole derivatives selectively targeting ALK5 (TGF-β type I receptor) demonstrated potent antifibrotic and anti-inflammatory effects in liver fibrosis models by dual inhibition of TGF-β/Smad signaling and inflammasome activation [76]. This evidence concerns the gene TGFB1 and Hepatic fibrosis.